Holen Sie sich die Stockscreener-App
32.98
1.79%
-0.60
Schlusskurs vom Vortag:
$33.58
Offen:
$33.75
24-Stunden-Volumen:
116.03K
Relative Volume:
0.42
Marktkapitalisierung:
$928.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-5.8921
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+0.70%
1M Leistung:
+10.15%
6M Leistung:
+34.83%
1J Leistung:
+50.05%
1-Tages-Spanne:
$32.72
$34.11
1-Wochen-Bereich:
$32.45
$35.87
52-Wochen-Spanne:
$16.54
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
32.98 | 921.79M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Is LENZ Therapeutics Inc. a good long term investmentFree Stock Market Beginners Guide - jammulinksnews.com
What drives LENZ Therapeutics Inc. stock priceConsistently high yield - jammulinksnews.com
LENZ Therapeutics Inc. Stock Analysis and ForecastHigh-yield growth strategies - jammulinksnews.com
What analysts say about LENZ Therapeutics Inc. stockMarket-beating returns - jammulinksnews.com
How LENZ Therapeutics Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
what makes lenz therapeutics inc. stock price move sharplyVolume Spike Monitors - newser.com
What makes LENZ Therapeutics Inc. stock price move sharplyFree Smart Money Group - Newser
Why LENZ Therapeutics Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect? - Yahoo Finance
Versant funds sell $6.5 million in Lenz Therapeutics (LENZ) - Investing.com Australia
Versant funds sell $6.5 million in Lenz Therapeutics (LENZ) By Investing.com - Investing.com South Africa
Leerink Partnrs Has Bearish Outlook for LENZ FY2028 Earnings - Defense World
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - 富途牛牛
LENZ Therapeutics Shares Soar 4.93% on Strategic Partnership, Regulatory Milestone - AInvest
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - VisionMonday.com
LENZ and Théa partner on Canadian commercialization of presbyopia eye drop - Eyes On Eyecare
LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada - Ophthalmology Times
Lenz Therapeutics stock gains as William Blair reiterates Outperform By Investing.com - Investing.com Nigeria
Lenz Therapeutics stock gains as William Blair reiterates Outperform - Investing.com
LENZ and Théa ink $70 million licensing deal for presbyopia treatment - Investing.com India
LENZ Therapeutics and Laboratoires Théa Announce Exclusive - GlobeNewswire
$70M Licensing Deal: LENZ Eyes Canadian Market with Breakthrough Presbyopia Treatment - Stock Titan
LENZ Therapeutics: A Pivotal Moment for Presbyopia and Potentially Transformative Returns - AInvest
LENZ Therapeutics: Presbyopia Eyedrops Look Promising (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell Microcap Value Index - MarketScreener
LENZ Therapeutics: Ready To Test Its Potential (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics reports results of stockholder vote By Investing.com - Investing.com Nigeria
LENZ Therapeutics reports results of stockholder vote - Investing.com
LENZ Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock By Investing.com - Investing.com South Africa
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock - Investing.com
Two Sigma Investments LP Has $493,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Transcript : LENZ Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZLENZ Therapeutics Reports Third Quarter 2024 Financial Results - mx.advfn.com
Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
BNP Paribas Financial Markets Sells 859 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN
Deutsche Bank AG Purchases 4,370 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Holdings Boosted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Jun 27 '25 |
Sale |
30.46 |
200,000 |
6,093,000 |
1,767,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
| Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):